Prostate Specific Antigen, Total
Also known as: PSA
Use
This test is used as a preferred initial screening for prostate cancer in conjunction with a digital rectal exam. It is also employed to monitor patients for recurrence of cancer. The Roche PSA electrochemiluminescent immunoassay aids in the detection of prostate cancer when used alongside a digital rectal exam in individuals aged 50 years and older. It is also indicated for the serial measurement of PSA to aid in prognosis and management of prostate cancer patients.
Special Instructions
Use the test in conjunction with a digital rectal exam for best results in detecting prostate cancer. Results from different test methods or kits cannot be used interchangeably.
Limitations
Elevated PSA concentrations can only suggest the presence of prostate cancer until a biopsy is performed. PSA concentrations can also be elevated in conditions such as benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy individuals or those with nonprostatic carcinoma.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 83112-3
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection.
Causes for Rejection
Grossly hemolyzed specimens. Vaginal washings.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 5 days |
| Frozen | 6 months |